Effect of liraglutide on epicardial adipose tissue thickness with echocardiography in patients with obese type 2 diabete
- PDF / 936,799 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 18 Downloads / 179 Views
ORIGINAL ARTICLE
Effect of liraglutide on epicardial adipose tissue thickness with echocardiography in patients with obese type 2 diabetes mellitus Ying Li 1 & Xuewei Liu 2 & Guangsen Li 1 & Ping Zhang 2 Received: 5 September 2019 / Accepted: 13 April 2020 / Published online: 18 May 2020 # Research Society for Study of Diabetes in India 2020
Abstract Background Liraglutide, an analogue of glucagon-like peptide 1 (GLP-1), indicated for the treatment of type 2 diabetes mellitus (T2DM), has shown the effect on loss of weight and adipose deposits. The study was to evaluate the effect of liraglutide on epicardial adipose tissue (EAT) with echocardiography in patients with obese T2DM controlled on liraglutide monotherapy. Methods A single-arm follow-up research was performed in our study. Thirty-six subjects with obese T2DM were enrolled in the study, who were administered with liraglutide monotheraphy daily. The study period was 3 months. EAT thickness was measured with echocardiography both before and after treatment in each subject; meanwhile, anthropometrics and biochemicals (fasting blood glucose and hemoglobinA1c) were also conducted. Results EAT thickness decreased significantly after three-month treatment, from 9.14 ± 2.39 to 6.42 ± 1.48 mm (p < 0.05). Anthropometrics including body weight, body mass index (BMI), waist circumference (WC), hip circumference (HC), and some biochemicals including fasting blood glucose (FBG), hemoglobinA1c (HbA1c), C-peptide, insulin, HOMA-IR, AST, ALT, and urinary albumin significantly improved (totally p< 0.05). Interestingly, the variation of EAT thickness had positive correlation with the variations of WC, HC, and BMI. Conclusions Liraglutide is beneficial to the decrease of EAT. EAT thickness can be measured with echocardiography to evaluate the effect of liraglutide in obese T2DM patients. Keywords Obese type 2 diabetes mellitus . Liraglutide . Epicardial adipose tissue . Echocardiography
Introduction According to World Health Organization, obesity is associated with diabetes by 44%. In recent years, the morbidity of diabetes is gradually increasing, especially obese type 2 diabetes mellitus (T2DM). It is worth highlighting that visceral fat accumulation is a noticeable risk factor for cardio-metabolic and coronary artery events [1]. Recently, the close affiliation between anatomy and function of ectopic visceral fat * Guangsen Li [email protected] * Ping Zhang [email protected] 1
Department of Ultrasound, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
2
Department of Endocrinology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
distribution has been paid more and more attention. Epicardial adipose tissue (EAT) is an organ special visceral fat deposit, surrounding the myocardium and coronary vessels without fibrous fascial tissue [2]. EAT thickness in groups with T2DM and obesity is thicker than that of normal population [3]. Thicken EAT secretes varieties of cytokines including inflammatory factors, adipoki
Data Loading...
